Multi-Cancer Early Detection: cancer screening beyond today's boundaries

For Life and Health (L&H) insurers, MCED tests may offer opportunities in supporting policyholders in living longer and healthier lives. The goals of MCED tests are clear: detect cancer earlier, which can allow for more effective treatment, improving survival rates and, ultimately, life expectancy. First generation MCED tests are in clinical trials, with some already commercially available. Work in this space is ongoing and efficacy and clinical utility of these tests continue to be assessed.  

As this new technology is in its infancy, there are still challenges for widespread clinical use. MCED tests may suggest early indications of cancer which cannot be verified using existing gold-standard diagnostic methods, therefore postponing treatment until a definitive diagnosis can be made. Early versions of these tests may lead to overdiagnosis, potentially resulting in patient distress, increased unnecessary treatments and related costs. L&H insurers will need to undertake risk assessments of MCED tests to evaluate potential implications on product design, underwriting guidelines, pricing and claims.

The full publication contains more detailed information on opportunities and challenges for MCEDs, the implications of MCED testing for L&H insurance companies, and an overview of selected MCED tests in development. See below to download the full report.